New pill challenges standard chemo for common adult leukemia
NCT ID NCT04075292
Summary
This study is comparing a newer, targeted pill called acalabrutinib against a standard combination of chemotherapy and immunotherapy (chlorambucil plus rituximab) for adults with previously untreated chronic lymphocytic leukemia (CLL). It is for older adults or younger adults with other health conditions. The main goal is to see which treatment is better at keeping the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100191, China
-
Research Site
Changchun, 130021, China
-
Research Site
Changsha, 410013, China
-
Research Site
Changzhou, 272100, China
-
Research Site
Guangzhou, 510100, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Guiyang, 550004, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Hefei, 230001, China
-
Research Site
Hefei, 230031, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanjing, 210029, China
-
Research Site
Qingdao, 110016, China
-
Research Site
Shanghai, 200025, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Shanghai, 200050, China
-
Research Site
Shenyang, 110001, China
-
Research Site
Shijiazhuang, 050020, China
-
Research Site
Suzhou, 215006, China
-
Research Site
Taiyuan, 030001, China
-
Research Site
Tianjin, 300020, China
-
Research Site
Xuzhou, 221000, China
-
Research Site
Zhengzhou, 450008, China
-
Research Site
Zhengzhou, 450052, China
-
Research Site
Baguio City, 2600, Philippines
-
Research Site
Cebu, 6000, Philippines
-
Research Site
Davao City, 8000, Philippines
-
Research Site
Makati, 1229, Philippines
-
Research Site
Manila, 1000, Philippines
-
Research Site
Quezon City, 1112, Philippines
-
Research Site
Chiayi City, 613, Taiwan
-
Research Site
Hualien City, 97002, Taiwan
-
Research Site
Kaohsiung City, 833, Taiwan
-
Research Site
Taichung, 404, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Taipei, 11217, Taiwan
-
Research Site
Bangkok, 10330, Thailand
-
Research Site
Bangkok, 10400, Thailand
-
Research Site
Bangkok, 10700, Thailand
-
Research Site
Chiang Mai, 50200, Thailand
-
Research Site
Hat Yai, 90110, Thailand
-
Research Site
Khon Kaen, 40002, Thailand
-
Research Site
Hanoi, 100000, Vietnam
-
Research Site
Ho Chi Minh City, 700000, Vietnam
Conditions
Explore the condition pages connected to this study.